Cellyan Biotechnology Co. Class AHKPD
13F holders, Q1 2026 (March 31)4holders
0new positions
0sold out
$0.57avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Cellyan Biotechnology Co. Class A (HKPD) in their 13F filings, unchanged from Q4 2025. 0 opened new positions and 0 sold out. The largest holders were StoneX Group Inc. ($22K), Clear Street Group Inc. ($7K) and Two Sigma Investments, LP ($6K).
- Company
- Cellyan Biotechnology Co. Class A
- CUSIP
- G6365B104
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 11,234 shares sold, net −11,234 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| StoneX Group Inc. | 0.00% | Reduce -9.0% | 39,395 | $22K |
| Clear Street Group Inc. | 0.00% | No change | 12,019 | $7K |
| Two Sigma Investments, LP | 0.00% | Reduce -35.3% | 10,832 | $6K |
| UBS Group AG | 0.00% | Reduce -92.8% | 110 | $63 |
"% of holder's portfolio" is HKPD's weight in each manager's 13F, not the share of Cellyan Biotechnology Co. Class A the manager owns.